NEW
YORK, June 20, 2023 /PRNewswire/ -- Oramed
Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com),
announced today that it has been selected to present an oral
abstract presentation at the American Diabetes Association's 83rd
Scientific Sessions, taking place between June 23-26,
2023 in San Diego, California.
The presentation will include an overview of data from Oramed's
Phase 2 oral insulin trial for the treatment of NASH as well as
discuss how oral insulin was found
to potentially reduce liver fibrosis and
fat in patients with NASH and Type 2
Diabetes.
Presentation Details:
Abstract title: Oral Insulin Alleviates
Liver Fibrosis and Reduces Fat in Patients with NASH and Type 2
Diabetes—Results of Phase II Clinical Trial
Session: Metabolic Liver Disease—From
Bench to Bedside
Date: Friday, June
23, 2023
Time: 3:15pm PST
The oral presentation will be delivered in-person at the
San Diego Convention Center in
San Diego, California and will
also be published on the journal Diabetes® website.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals
(Nasdaq/TASE: ORMP) is a platform technology pioneer in the field
of oral delivery solutions for drugs currently delivered via
injection. The Company's novel Protein Oral Delivery (POD™)
technology is designed to protect drug integrity and increase
absorption. Oramed has offices in the
United States and Israel.
For more information, please visit www.oramed.com.
Forward-looking statements: This press release
contains forward-looking statements. For example, we are using
forward-looking statements when we discuss the potential of
oral insulin to
reduce liver fibrosis and fat in
patients with NASH and Type 2 Diabetes. These forward-looking
statements are based on the current expectations of the management
of Oramed only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements, including
the Company's process to evaluate strategic options; the terms,
timing, structure, benefits and costs of any strategic transaction
and whether any transaction will be consummated at all; the impact
of any strategic transaction on the Company; the outcomes of any
litigation, regulatory proceedings, inquiries or investigations to
which the Company may be subject; the ability to obtain financing
or third-party approvals as needed; our ability to achieve the
intended benefits of our strategic initiatives; the risks and
uncertainties related to the progress, timing, cost, and results of
clinical trials and product development programs; difficulties or
delays in obtaining regulatory approval or patent protection for
our product candidates; competition from other pharmaceutical or
biotechnology companies; and our ability to obtain additional
funding required to conduct our research, development and
commercialization activities. In addition, the following factors,
among others, could cause actual results to differ materially from
those described in the forward-looking statements: changes in
technology and market requirements; delays or obstacles in
launching our clinical trials; changes in legislation; inability to
timely develop and introduce new technologies, products and
applications; lack of validation of our technology as we progress
further and lack of acceptance of our methods by the scientific
community; inability to retain or attract key employees whose
knowledge is essential to the development of our products;
unforeseen scientific difficulties that may develop with our
process; greater cost of final product than anticipated; loss of
market share and pressure on pricing resulting from competition;
laboratory results that do not translate to equally good results in
real settings; our patents may not be sufficient; that products may
harm recipients; and other factors discussed in the "Risk Factors"
section of the Company's most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, which are on file with
the Securities and Exchange Commission and in other
filings that the Company makes with the Securities and
Exchange Commission in the future. All of these factors could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events.
Company Contact:
Zach
Herschfus
+1-844-9-ORAMED
zach@oramed.com
Logo -
https://mma.prnewswire.com/media/1724339/Oramed_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/oramed-to-present-at-the-83rd-american-diabetes-association-conference-301855053.html
SOURCE Oramed Pharmaceuticals Inc.